With a complete response letter for its 131I-omburtamab, Y-mAbs Therapeutics Inc. seems ready to put the B7-H3-directed radiolabeled murine monoclonal antibody to the side and prioritize its development platform and already-approved neuroblastoma drug.
The company said on 1 December that the US Food and Drug Administration had issued a CRL for omburtamab for...